vs
BioNexus Gene Lab Corp（BGLC）与Celcuity Inc.（CELC）财务数据对比。点击上方公司名可切换其他公司
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
Celcuity Inc.是一家临床阶段生物技术企业，专注于肿瘤学领域，通过专属功能性细胞分析技术开发个性化癌症治疗方案，致力于满足难治性实体瘤患者未被覆盖的医疗需求，主要运营范围覆盖美国及全球生物制药合作网络。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
BGLC
CELC
| Q4 25 | $483.8K | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $2.3M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $2.4M | — |
净利润BGLCCELC
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-709.0K | — | ||
| Q2 25 | $-616.2K | — | ||
| Q1 25 | $-623.3K | — | ||
| Q4 24 | $-348.3K | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $199.1K | — | ||
| Q1 24 | $-103.8K | — |
毛利率BGLCCELC
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
营业利润率BGLCCELC
| Q4 25 | -213.5% | — | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -27.0% | — | ||
| Q1 25 | -28.9% | — | ||
| Q4 24 | -16.5% | — | ||
| Q3 24 | -50.9% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | -3.3% | — |
净利率BGLCCELC
| Q4 25 | -214.2% | — | ||
| Q3 25 | -27.9% | — | ||
| Q2 25 | -27.3% | — | ||
| Q1 25 | -29.2% | — | ||
| Q4 24 | -13.8% | — | ||
| Q3 24 | -51.1% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | -4.4% | — |
每股收益（稀释后）BGLCCELC
| Q4 25 | — | — | ||
| Q3 25 | $-0.40 | — | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $-0.75 | — | ||
| Q2 24 | $0.11 | — | ||
| Q1 24 | $-0.01 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
